STAT News: obesity drugmakers are testing them in children as young as six
Manufacturers of obesity treatment drugs are testing such medications in children as young as six. This was reported by STAT News in the edition of its biotechnology newsletter, The Readout, published on September 15, 2026.
Obesity drug trials
The headline of The Readout edition states that developers of obesity drugs are conducting trials involving children as young as six. No other details about these studies are provided in the available excerpt of the material.
More current news is available on the UA.News Telegram channel Telegram.
Vera data on kidney drug
In the same edition, Vera said that its recently launched drug stabilized kidney function in a two-year study involving people with a chronic autoimmune kidney disease. According to the company, the treatment also reduced the risk of death related to kidney disease and other complications. Vera plans to seek full approval for the drug.
Legend Biotech also appointed Ingrid Zhang as its new chief executive officer. Zhang was previously a top executive at Novartis and replaced Ying Huang, who left the position in July.
